- Home
- JKHY vs RPRX Comparison
JKHY vs RPRX Comparison
Compare JKHY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JKHY
- RPRX
- Stock Information
- Founded
- JKHY 1976
- RPRX 1996
- Country
- JKHY United States
- RPRX United States
- Employees
- JKHY N/A
- RPRX N/A
- Industry
- JKHY Retail: Computer Software & Peripheral Equipment
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- JKHY Technology
- RPRX Health Care
- Exchange
- JKHY Nasdaq
- RPRX Nasdaq
- Market Cap
- JKHY 12.1B
- RPRX 13.9B
- IPO Year
- JKHY N/A
- RPRX 2020
- Fundamental
- Price
- JKHY $178.28
- RPRX $34.86
- Analyst Decision
- JKHY Hold
- RPRX Strong Buy
- Analyst Count
- JKHY 9
- RPRX 3
- Target Price
- JKHY $184.22
- RPRX $47.33
- AVG Volume (30 Days)
- JKHY 536.6K
- RPRX 4.8M
- Earning Date
- JKHY 05-06-2025
- RPRX 08-07-2025
- Dividend Yield
- JKHY 1.31%
- RPRX 2.53%
- EPS Growth
- JKHY 13.10
- RPRX 37.60
- EPS
- JKHY 5.87
- RPRX 2.45
- Revenue
- JKHY $2,319,828,000.00
- RPRX $2,263,845,000.00
- Revenue This Year
- JKHY $8.37
- RPRX $29.35
- Revenue Next Year
- JKHY $6.79
- RPRX $7.58
- P/E Ratio
- JKHY $30.26
- RPRX $14.18
- Revenue Growth
- JKHY 5.92
- RPRX 1.13
- 52 Week Low
- JKHY $158.62
- RPRX $24.05
- 52 Week High
- JKHY $196.00
- RPRX $35.38
- Technical
- Relative Strength Index (RSI)
- JKHY 45.57
- RPRX 61.71
- Support Level
- JKHY $178.58
- RPRX $33.37
- Resistance Level
- JKHY $181.20
- RPRX $35.38
- Average True Range (ATR)
- JKHY 2.70
- RPRX 0.60
- MACD
- JKHY -0.38
- RPRX 0.12
- Stochastic Oscillator
- JKHY 16.78
- RPRX 80.95
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for us banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.